Aclaris Therapeutics, a clinical-stage biotech developing topical drugs for skin lesions, filed on Monday with the SEC to raise up to $86 million in an initial public offering.
The Malvern, PA-based company, which was founded in 2012, plans to list on the Nasdaq under the symbol ACRS. Jefferies, Citi and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
